Description: FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.
Home Page: fluoguide.com
Ole MaalOees Vej 3
Copenhagen,
2200
Denmark
Phone:
45 31 22 66 60
Officers
| Name | Title |
|---|---|
| Mr. Morten Albrechtsen B.B.A., M.D., BBA | Chief Exec. Officer |
| Mr. Henrik Hang | Chief Financial Officer |
| Prof. Andreas Kjaer M.D., M.Sc., Ph.D. | CSO, CMO, Head of Scientific Advisory Board & Director |
| Dr. Grethe Nørskov Rasmussen M.Sc., Ph.D. | Chief Devel. Officer |
| Dorthe Gronnegaard Mejer | VP of Clinical Devel. |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.8612 |
| Price-to-Sales TTM: | 348.5461 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |